|
Balance Sheet Cash Flow Statement 88 Sidney St. Cambridge, MA 02139-4234 MA Tel. 617-494-0171 Fax 617-494-9263 |
Type: Public
On the web:
http://www.alkermes.com
Employees:
570
Employee growth: (6.6%)
Alkermes, whose name is Arabic for "magic potion," is working some biotech alchemy. The firm uses its proprietary drug-delivery systems to make fragile biotech compounds that require less frequent dosing or provide more targeted delivery. Focusing on widespread diseases like diabetes, central nervous system disorders, and addiction, it has a couple of drugs on the market that use its injectable extended-release technology, which lets patients take a drug once or twice a month, rather than once or twice a day. One such drug is Risperdal Consta, a long-acting version of Janssen's schizophrenia medication Risperdal. Another is Vivitrol, a treatment for alcohol dependence that the company markets itself.
Key numbers for fiscal year ending March, 2009:
Sales: $326.8M
One year growth: 35.8%
Net income: $130.5M
Income growth: (21.8%)
Officers:
Chairman: Richard F. Pops
President, CEO, and Director: David A. Broecker
SVP and COO: Gordon G. Pugh
Competitors:
Bristol-Myers Squibb
Forest Labs
Johnson & Johnson
